title: Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C.
abstract: In a study assessing factors associated with a good or a poor response to interferon treatment in patients with chronic hepatitis type C, we analyzed serum samples taken from 26 interferon-treated patients and found further evidence that infection with genotype II is associated with a poor response. Whereas all seven patients with group III genotype tested showed a good response (normalization of alanine aminotransferase level for more than 6 months), only 10 of 19 (53%) patients infected with group II genotype showed a good response. We also observed that 16 of 17 (94%) patients who exhibited a rapid virus titer decrease during the first 2 weeks of treatment later showed a good response. In contrast, only three of nine (33%) patients with an initially slow viral decrease eventually showed a good response (p<0.04). None of the 26 control patients exhibited a marked virus decrease or normalization of serum alanine aminotransferase level. Interestingly, high degrees of sequence variability were seen in three patients with group II hepatitis C virus who responded poorly to the therapy. All three showed slow decreases in virus titer during the first 2 weeks of treatment. In contrast, patients with genotype II who showed a good response to treatment were seen to have very few mutations. In three patients with genotype III who had responded well to interferon treatment, all showed very little amino acid sequence variability in the hypervariable region compared with patients with genotype II who had responded poorly to interferon treatment. These data suggest that a slow decrease in virus titer during the beginning of interferon treatment and a high degree of sequence variability, both of which are often seen in patients with group II genotype, are associated with poor response to interferon treatment.
authors: Department of Gastroenterology, Toranomon Hospital, Okinaka Memorial Institute for Medical Study, Tokyo, Japan.
authors: K
authors: K
authors: Chayama
authors: A
authors: A
authors: Tsubota
authors: Y
authors: Y
authors: Arase
authors: S
authors: S
authors: Saitoh
authors: K
authors: K
authors: Ikeda
authors: T
authors: T
authors: Matsumoto
authors: M
authors: M
authors: Hashimoto
authors: M
authors: M
authors: Kobayashi
authors: M
authors: M
authors: Kanda
authors: T
authors: T
authors: Morinaga
mesh_terms: D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D001483:Base Sequence; D002908:Chronic Disease; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000737:chemistry / Q000235:genetics*; D006526:Hepatitis C / Q000628:therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D017361:Viral Nonstructural Proteins / Q000737:chemistry*
chemical_list: D017361:Viral Nonstructural Proteins; D007372:Interferons